We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West’s Ready Pack™ system with adaptiQ® products, that are part of the SCHOTT iQ® platform, enables both small and large customers the convenience and flexibility to purchase small quantities of sterile, high-quality, ready-to-use (RTU) components. Ready Pack system components are packaged separately but tested for use as an integrated system. Designed to support customers throughout small-scale R&D, clinical trials, fill-finish evaluation, and commercial-scale manufacturing, the Ready Pack system is a comprehensive, scalable packaging solution that helps customers get to market faster by making the same high-quality packaging available from start to finish. Ready Pack systems keep up with emerging ISO standards and our Ready Pack offering includes the latest glass packaging formats such as adaptiQ® clip nest, cup nest, and tray solution.
In a joint study with SCHOTT, West tested combinations of SCHOTT’s highest quality ISO No Blowback (NBB) vials with West’s sterile, RU NovaPure® Serum/Lyo 4023/50 Gray stoppers and gamma-sterilized Flip-Off® CCS/CCRS TruEdge™ seals for Container Closure Integrity (CCI). Results indicate these combinations offer viable closure systems over 24 months when used as in the study. See Technical Report 2020/219 “Container Closure Integrity Testing on EU NovaPure Closure Configurations for Ready Pack™ System with SCHOTT No Blowback Vials.”
West is committed to the safe and efficient delivery of drug products, in particular, helping customers get to market more quickly. West’s Ready Pack system helps to achieve these goals. For more information, contact an Account Manager or Technical Customer Support (TCS) representative.
Ready Pack™, NovaPure®, Flip-Off®, and TruEdge™ are trademarks and registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
adaptiQ® and SCHOTT iQ® are registered trademarks of SCHOTT AG.
Since our Eschweiler’s site founding in 1960 as Pharma-Gummi, we have been helping to support our overall company mission to ensure the development and delivery of lifesaving, life-enhancing medicines for patients around the world. In the current COVID-19 pandemic, we have a special role to play: through these challenging times, vaccine developers have trusted West as a partner of choice to help protect their sensitive biomolecules. If you’ve ever been vaccinated, or if you or a loved one has ever needed to take an injected medicine, you’ve probably encountered a West product.
United States Pharmacopeia (USP) requirements for elastomeric components of container closure systems used for parenteral products are changing. The original USP chapter for elastomeric components used in injectable drug packaging was <381> Elastomeric Components in Injectable Pharmaceutical Production Packaging/Delivery Systems. This addressed characterizing for biological reactivity, physicochemical testing and functionality testing and compliance was typically a supplier responsibility. The new chapter, USP <382> Elastomeric Component Functional Suitability in Parenteral Product Packaging/Delivery Systems, will become effective on December 1, 2025. This will update the functionality tests for elastomers, whereas the functionality testing portion of USP <381> will be omitted. Under the new chapter, it will be the drug manufacturer’s responsibility to meet the functionality requirements on the final system.
<p>We are proud to announce our inaugural Corporate Responsibility Report. West’s commitment to sustainability and remaining active in the areas where we live and work are integral to West’s culture. In Parts 1-3 of this five-part blog series on the report, we focused on West’s efforts in <a href="/zh-cn/blog/2017/june/corporate-responsibility-for-2016">Compliance and Ethics</a>, <a href="/zh-cn/blog/2017/july/corporate-responsibility-report-part-2-philanthropy">Philanthropy</a> and <a href="/zh-cn/blog/2017/july/corporate-responsibility-report-part-3-celebrating-diversity">Diversity</a>.</p><p>The fourth part of the five-part series on West’s Corporate Responsibility discusses West’s Health and Safety programs.</p>
We are delighted to share that West has been honored at the Korea Bioprocessing Excellence Awards (KBEA) for the second year in a row. This year, we were recognized as the grand winner of the Best Bioprocessing Supplier Award: Fill-Finish.
The Japanese Pharmacopeia (JP) has updated chapter 7.03 “Test for Rubber Closures for Aqueous Infusions” and the last date to transition to the new version is <strong>September 30, 2015</strong>.
English
Chinese
